Loading...
•
Dec 31, 2024
Ionis Q4 2024 Earnings Report
Ionis Q4 2024 Earnings Report showed a revenue decline and increased losses, but the company exceeded guidance and launched its first independent medicine.
Key Takeaways
Ionis Pharmaceuticals reported Q4 2024 revenue of $227,000,000, a 30.15% decline YoY. The company posted a net loss of $104,000,000, compared to a loss of $9,000,000 in Q4 2023. Despite these losses, Ionis exceeded its financial guidance and launched TRYNGOLZA, its first independently commercialized product.
Revenue declined by 30.15% YoY to $227,000,000.
Net loss increased to $104,000,000 from $9,000,000 YoY.
The company launched TRYNGOLZA, its first independent product.
Ionis exceeded its 2024 financial guidance.
Revenue by Segment
Forward Guidance
Ionis expects a shift toward increasing commercial revenue in 2025, investing in independent product launches while maintaining a strong financial position.
Positive Outlook
- Revenue expected to exceed $600,000,000 in 2025.
- Company shifting toward increasing commercial revenue sources.
- Continued investment in TRYNGOLZA and upcoming product launches.
- Cash position expected to remain strong at ~$1,700,000,000.
- Pipeline progress with multiple upcoming clinical milestones.
Challenges Ahead
- Operating loss expected to be below $495,000,000.
- R&D expenses expected to remain high due to ongoing trials.
- Market acceptance of new products remains uncertain.
- Regulatory risks could impact launch timelines.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...